Patients who are diagnosed with stage IV metastatic melanoma have an estimated 5-year relative survival rate of only 17%. Randomized controlled trials of recent US Food and Drug Administration-approved immune checkpoint inhibitors-pembrolizumab (PEM), nivolumab (NIVO), and ipilumumab (IPI)-demonstrate improved patient outcomes, but the optimal treatment sequence in patients with BRAF wild-type metastatic melanoma remains unclear. To inform policy makers about the value of these treatments, we developed a Markov model to compare the costeffectiveness of different strategies for sequencing novel agents for the treatment of advanced melanoma.
INTRODUCTION
Melanoma is the fifth most common cancer in the United States, with more than 75,000 new cases and 10,000 deaths annually. 1 Metastatic melanoma is an aggressive disease and carries a poor prognosis; five-year relative survival rates for local and metastatic melanoma are 98% and 17%, respectively.
2-4 Approximately 40% to 60% of melanomas contain a mutation in the BRAF proto-oncogene, which leads to constitutive activation of downstream signaling in the mitogenactivated protein kinase pathway. 5, 6 Dacarbazine, once the mainstay chemotherapeutic agent for the treatment of metastatic disease, has been replaced by recent US Food and Drug Administration (FDA)-approved immune checkpoint inhibitors, which have demonstrated significant survival improvement -ipilimumab (IPI; FDA approval in 2011), pembrolizumab (PEM; FDA approval in 2014), and nivolumab (NIVO; FDA approval in 2014). IPI, a first-inclass recombinant human IgG1 monoclonal antibody, binds to cytotoxic T-lymphocyte associated antigen-4, which allows for enhanced T-cell activation and proliferation. 7 A phase III trial (clinical trial information: NCT00094653) evaluated first-line IPI for the treatment of patients with advanced melanoma; a statistically significant improvement in median overall survival (OS) among patients who were treated with IPI compared with dacarbazine resulted in 5-year survival rates of 18.2% versus 8.8%, respectively. 8 NIVO and PEM are IgG4k antiprogrammed death protein-1 (anti-PD-1) monoclonal antibodies. Multiple phase III trials have evaluated their efficacy in patients with advanced melanoma: NIVO versus first-line dacarbazine in CheckMate-066 9 ; first-line NIVO alone, combination NIVO + IPI, or IPI alone in Checkmate-067 10 ; second-line NIVO versus chemotherapy in CheckMate-037
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; first-line PEM at two dosing schedules compared with first-line IPI in KEYNOTE-006 12 ; and second-line IPI versus palliative care. [8] [9] [10] [11] [12] Although immune checkpoint inhibitors have clearly improved outcomes in patients with metastatic disease, they are associated with adverse events (AEs) and significant cost. In our current health care environment, policy makers, providers, and patients alike need sound evidence as a framework for determining the value of different therapeutic alternatives in oncology. As such, we sought to evaluate the cost-effectiveness of currently available therapies for patients with BRAF wild-type advanced melanoma by using recently reported phase III trial data.
MATERIALS AND METHODS

Model Overview
A comprehensive Markov model was developed to analyze the costeffectiveness of BRAF wild-type advanced melanoma management from a US payer perspective (Fig 1 and Appendix Fig A1, online only) . We modeled a hypothetical cohort of patients with advanced melanoma with the same characteristics as those patients enrolled in CheckMate-066, CheckMate-067, CheckMate-037, KEYNOTE-006, and NCT00094653. [8] [9] [10] [11] [12] Our assumptions describing progression-free survival (PFS) and OS treatment benefits were based on survival curves from these phase III trials. The model evaluated six treatment options: first-line NIVO followed by second-line IPI; first-line NIVO + IPI followed by second-line carboplatin and paclitaxel; 10 first-line PEM every 2 weeks followed by second-line IPI; first-line PEM every 3 weeks followed by second-line IPI; first-line IPI followed by second-line NIVO; and first-line dacarbazine followed by second-line IPI and third-line NIVO. After initial therapy, patients could experience a response and continue therapy-either with or without grade 3 or 4 nonimmune AEs or immune-related AEs (irAEs)-or experience progressive disease (PD) and switch to second-line treatment. Patients on second-line, or third-line, therapy could experience treatment response or PD, the latter of which would result in a cessation of therapy and the commencement of palliative care and death. During any line of treatment, patients could end current therapy as a result of PD or grade 3 or 4 AEs observed in the associated clinical trials.
Model outcomes include treatment costs (in 2016 US$) and qualityadjusted life years (QALYs). We calculated the incremental cost-effectiveness ratios (ICERs)-the difference in costs divided by the difference in QALYs-to compare two treatment strategies. Examining the results in this way, first-line pembrolizumab administered every 3 weeks followed by second-line ipilimumab proved to be the dominant treatment. All costs and health outcomes were discounted by 3% annually. 13 The model was programmed by using the decision analytic software TreeAge Pro 2016 (TreeAge Software, Williamstown, MA).
Model Transitions and Survival Estimates
The model simulated transitions between health states with a cycle length of 6 weeks, which was chosen to match the time interval between patient status assessments in the clinical trials. Our model considered changes in quality-adjusted survival as a result of grade 1 and 2 or 3 and 4 AEs, and irAEs. Patients transitioned between health states on the basis of calculated transition probabilities from PFS, OS, and discontinuation rates from phase III trials associated with the respective treatments. Engauge Digitizer software was used to extract data points from the curves; these data points were then used to fit parametric survival models.
14 Survival distributions were tested for goodness-of-fit for all curves, 15,16 and we used a Weibull distribution to model survival because it can have an increasing hazard rate and is suitable for modeling events that occur early during follow-up periods. Patients who achieved a response who were in the grade 3 and 4 AEs or irAE state accumulated benefits and costs-similar to patients who achieved response, but without the grade 3 and 4 AE or irAE health state-and only transitioned to the PD health state upon documented disease progression (determined by immune response criteria) 17 and the respective clinical trial data. With the exception of the dacarbazine arm, which included a third-line option, patients who experienced PD after second-line therapy subsequently exited the model. The probability of transitioning to death during each cycle was defined as the maximum value of observed mortality rate by using survival data from each trial and the other-cause (background) mortality rate. Othercause mortality for each age group was estimated from US life tables. 18 
Utilities and Costs
QALYs were calculated by multiplying the time spent in a given state (in life-years) by the utility score (a health status value from 0 for death to 1 for perfect health) associated with that state. 19 The utility weights of all health states and AEs were derived from published studies. 20, 21 We jco.org assigned a utility of 0.80 for all patients in first-line therapy, 0.88 for patients who achieved complete or partial treatment response, and 0.52 for PD (Appendix Table A1 , online only). The model considered both grade 1 or 2 and 3 or 4 nonimmune and irAEs as measured by temporary health utility decrements as well as increased treatment-related costs (Table 1 and  Appendix Table A2 , online only).
Direct medical costs considered were as follows: physician visits, hospitalization costs, drug acquisition costs, drug infusion costs, laboratory tests (inpatient and/or outpatient), radiographic tests (inpatient and/or outpatient), and hospital encounters (Table 2 ). In addition, we included treatment costs for nonimmune and irAEs from each trial (Appendix Table A2 ). We used reimbursement rates provided by the Centers for Medicare & Medicaid Services (CMS), the largest public payer in the United States, which are generally lower than reimbursement rates for private insurers. 26 To estimate the unit price of each drug, we used average sales price data from CMS 25 ; the average sales price of oral medications not listed in CMS were derived from the Medicare plan finder online tool. 27,28 Medication costs were calculated by using a basecase patient with a height of 165 cm and weight of 70 kg, with a subsequent body surface area of 1.79 m 2 .
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Cost of hospitalization included inpatient physician service fees and hospital reimbursement on the basis of the length of stay diagnosis-related group code corresponding to the AE. For each treatment strategy, the cost of each AE was obtained by multiplying the incidence of the AE by its associated unit cost. Management of AEs were based on published guidelines, and AE costs were calculated by using the Medicare physician fee schedule. 30 Fees for outpatient physician visits were based on their health care procedure coding system and/or their current procedure terminology code using validated methods. 31 
Sensitivity Analysis
To evaluate the robustness of the model and address the uncertainty in estimates of variables, we performed a series of sensitivity analyses. AEs and utilities were varied over their 95% CIs. Drug costs were varied within 6 20% of their baseline values, in accordance with established approaches. [32] [33] [34] In univariable sensitivity analyses, we varied the value of one parameter at a time over its defined range and examined the effect of each parameter individually on ICERs for all variables in Tables 1 and 2 and  Appendix Tables A1 to A3 (online only) .
To account for variation in multiple parameters at once, we also completed probabilistic sensitivity analyses; we performed 10,000 Monte Carlo simulations, each time randomly sampling from the distributions for all parameters simultaneously. We followed recommended distributions on the basis of parameter types, and assumed g-distribution for costs and b-distribution for the incidence of AEs and utility values 35, 36 (Tables 1 and 2 and Appendix Tables A1 to A3 ). To illustrate the uncertainty surrounding our base-case estimate of costeffectiveness, cost-effectiveness acceptability curves were derived and used to project the probability that each treatment strategy was the most cost-effective under various willingness-to-pay (WTP) thresholds.
RESULTS
The base-case cost and effectiveness of each treatment sequence, as well as individual therapy choices for first-, second-, and third-line therapy, are listed in Table 3 . Examining all treatment strategies incrementally, first-line PEM every 3 weeks followed by secondline IPI was less costly and more effective than treatment sequences that involved first-line IPI, first-line dacarbazine, and first-line PEM every 2 weeks (Appendix Fig A2, online only) . Compared with the treatment strategy with PEM every 3 weeks, first-line NIVO was associated with incremental costs and benefits of $44,593 and 0.16 QALYs, respectively (ICER = $278,706/QALY), whereas first-line NIVO + IPI was the least cost-effective strategy and was associated with an additional $78,809 in costs and benefits of 0.18 QALYs. In addition, ICERs for each pairwise comparison are listed in Table 4 as a way to understand individual choices between two competing treatment strategies. jco.org
One-way sensitivity analyses demonstrated that differences in drug cost, discontinuation rates, and increased disutility associated with IPI were the most influential factors within the model (Appendix Figs A3 and A4, online only) . Results of the probabilistic sensitivity analysis are shown in Fig 2. First-line PEM every 3 weeks was the most cost-effective treatment with a probability of remaining cost-effective of 69% of sampled parameters, using a WTP of $100,000/QALY.
DISCUSSION
After the results of CheckMate-066, the FDA approved combination NIVO + IPI for patients with treatment-naïve BRAF wildtype advanced melanoma, and this combination became a new standard-of-care for fit, newly diagnosed patients with advanced melanoma. 9, 37 More than 20 years ago, US patients with advanced NOTE. This table reports base-case results of each treatment strategy compared with each alternative option in an individual, pairwise fashion. In doing so, ICERs are reported as the comparison between two arms and may be useful when choosing between two therapeutic strategies. For example, when choosing between nivolumab and pembrolizumab administered every 3 weeks, ICER is $297,287/quality-adjusted life-year. Abbreviations: DAC, dacarbazine; ICER, incremental cost-effectiveness ratio; IPI, ipilimumab; NIVO, nivolumab; PEM, pembrolizumab. *Carboplatin plus paclitaxel. melanoma had medical costs of $249 million per year and perpatient lifetime costs (time-of-diagnosis to death) of $28,210. 24, 38 In the past several years, annual health care costs are estimated at . $600 million, with per-patient lifetime costs of approximately $200,000.
22,23,39-41 This dramatic increase has been attributed to higher costs related to drug acquisition, diagnosis and treatment of brain metastases, and end-of-life care, as well as managing irAEs, which are unique to these newer immunotherapeutic agents. 42, 43 Unlike the National Institute for Health and Care Excellence, the FDA does not take into account costeffectiveness when making decisions regarding drug approvals, and once approved, CMS is prohibited from considering costeffectiveness in reimbursement and coverage decision-making. 44 Whereas definitions of cost-effectiveness vary, an ICER of # $150,000 per QALY averted or less than three times the annual gross domestic product per capita 44, 45 are commonly used thresholds to determine cost-effectiveness of therapy. Results of recent cost-effectiveness analyses in advanced melanoma have been mixed.
46-49 Although immune-based therapy significantly improves outcomes in patients with advanced BRAF wild-type melanoma, the optimal sequence and/or combination of immune-based therapies remains unclear from a value standpoint.
To our knowledge, our model provides the most comprehensive assessment to date that compares different treatment strategies for patients with BRAF wild-type advanced melanoma; our model also demonstrates that treatment with a first-line PD-1 inhibitor followed by second-line IPI seems to be the most effective and cost-effective strategy. These options (NIVO and PEM every 3 weeks) fall below a WTP of $150,000/QALY and the National Institute for Health and Care Excellence standard. 44 Indeed, first-line PEM every 3 weeks is more cost-effective than even first-line dacarbazine, despite the large difference in drug acquisition cost. In contrast, combination NIVO + IPI does not seem to be a cost-effective first-line strategy; substantial price reductions are needed to make this a viable option. In our model, sequential therapy, compared with combination therapy, allowed IPI to be used as an efficacious treatment option for second-line use and was also associated with improved patient quality of life, fewer serious AEs that required prolonged hospitalizations and costly treatment interventions, and a lower rate of permanent drug discontinuation.
The most influential factors driving our model were the drug acquisition cost of first-line IPI and the cost of managing irAEs. Despite only providing 0.31 QALYs in the first-line setting, IPI was associated with a drug acquisition cost more than that of PEM and NIVO combined, both of which provided higher QALYs in the first-line setting. This was surprising given that patients who were treated with IPI received a fixed number of doses (four) compared with indefinite dosing of anti-PD-1 therapy. In addition, our model accounted for the high discontinuation rate and subsequently reduced number of doses among those patients receiving first-line IPI (monotherapy [14%] or combination therapy [37%]). High first-line IPI costs were likely a result of a relatively large percentage of patients receiving first-line IPI who developed grade 3 and 4 AEs or irAEs, which are associated with lengthy hospitalizations, diagnostic imaging, and prolonged treatment course.
43,50 Sensitivity analysis also highlighted the importance of receiving anti-PD-1 therapy in the first-line setting, as opposed to later lines of treatments, and suggested that a particular opportunity for maximizing the effectiveness of these agents may exist in the first-line setting. This was most evident with NIVO, which provided 0.44 QALYs in the first-line setting, but only 0.20 QALYs in the second-line setting. This difference highlights the precipitous decline in treatment efficacy, or perhaps more likely, the decreased relative fitness of patients and decreased tolerance to second-line and third-line therapy. When comparing the different immune checkpoint inhibitors and dosing schedules in the first-line setting, QALYs were comparable but drug acquisition costs were quite different, which suggests Cost-effectiveness acceptability curve. Results of the probabilistic sensitivity analysis on the basis of 10,000 iterations of the model, which drew parameters for each input simultaneously from probability distributions to indicate uncertainty about whether the treatment sequences are cost-effective given different willingness-to-pay thresholds. A count is obtained of the proportion of simulated incremental cost-effectiveness ratio values that are acceptable at each willingness-to-pay threshold, which is shown on the y-axis. For example, pembrolizumab administered every 3 weeks was found to be cost-effective in 69% of simulations at a willingness-to-pay threshold of $100,000. IPI, ipilimumab; NIVO, nivolumab; PEM, pembrolizumab.
jco.org that treatment dose and/or schedule may not be as important as merely receiving therapy that provides negative regulation of the immune checkpoint blockade. In other words, the noninferiority of PEM 2 mg/kg versus 10 mg/kg; PEM every 2 weeks versus PEM every 3 weeks; IPI for four cycles versus two cycles as a result of serious AEs, prompting drug discontinuation; and NIVO versus NIVO + IPI, which implies that initial therapy with an immune checkpoint inhibitor is more fundamental than the specific, chosen agent.
Our model relied on commonly used assumptions worth noting. First, administration of PEM (first-and second-line) in our model was the same dose that received accelerated FDA approval. This was based on PEM's breakthrough activity in a phase II trial with IPI-refractory disease 49 ; although not powered to detect a difference, patients in KEYNOTE-002 were randomly assigned to 2 mg/kg versus 10 mg/kg dosing, with comparable activity and considerably fewer grade 3 and 4 AEs or irAEs at the lower dose. In the KEYNOTE-006 trial used in our model, the higher dose of PEM was used for both dosing schedules and was associated with more serious irAEs than those observed with the lower dose. 12, 51 Ongoing clinical trials of PEM use a fixed dosing schema instead of weight-based dosing.
52 A similar approach was taken with first-and second-line IPI, where the dose varied from trial to trial. Whereas low-dose IPI (3 mg/kg) is FDAapproved for use in advanced melanoma, 9 the higher 10 mg/kg dose used in some of the clinical trials was associated with more grade 3 and 4 irAEs; 10 mg/kg is currently FDA-approved for adjuvant use in patients with high-risk stage III melanoma to decrease the risk of recurrence.
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Our study had some limitations that merit discussion. As with many cost-effectiveness studies, our model was based on data from previously published trials and not data that were prospectively collected; however, a benefit of this approach is that, by using national averages for costs, we accounted for regional variations in our estimates. Our analysis was also limited by data availability, particularly with regard to published survival data. 54 There were differences in treatment and patients characteristics (ie, BRAF status) across clinical trials that may have influenced model parameters. Second, health utility estimates in this model, although used in previously published melanoma economic models, may not accurately reflect the hypothetical population used in the current analysis. An updated health utility measure for patients with advanced melanoma in populations with targeted and immune-based therapy might improve accuracy and robustness. Third, although we attempted to account for the most common clinical scenarios and most accurately emulate clinical practice, it is likely we did not account for all possible scenarios. For example, in clinical practice, the increase in size of cancer on radiographic imaging does not necessarily indicate PD or require immediate second-line therapy; however, this was likely minimized in our model, as most trials used immune response criteria, as opposed to the commonly used Response Evaluation Criteria in Solid Tumors (RECIST) criteria, which is typically used to gauge solid tumor treatment response. RECIST fails to account for delayed responses and the pseudoprogression phenomenon, both of which are commonly encountered when evaluating radiographic imaging of patients who were treated with immunebased therapy. 54, 55 Finally, our analysis did not incorporate programmed deathligand 1 (PD-L1) status and testing, primarily because of the paucity of data. Of the included phase III trials, only Checkmate-067 10 reported secondary end points (PFS and objective response) that showed a significant benefit for combination IPI plus NIVO versus single-agent NIVO in PD-L1-negative, not PD-L1-positive, patients in a subgroup analysis. In addition to the issue of statistical power, PD-L1 testing is not currently standardized and the optimal cutoff for PD-L1 is still unclear. As the field grows, future costeffectiveness analyses should incorporate PD-L1 status into the decision-making process.
Despite these limitations, our model has many strengths. We accounted for the high rate of patients who discontinued treatment as a result of toxicity but who continued to maintain a response, a feature that is unique to immunotherapy. We accounted for all treatment-related costs from a CMS perspective, including grade 1 to 4 AEs or irAEs. Finally, our model incorporated different therapeutic sequences, rather than a comparison of two treatments, and this emulates routine clinical practice of systemic chemotherapy and immunotherapy delivery.
The current cost-effectiveness analysis should be included in the decision-making process with additional efficacy data (and individual patient data) to make recommendations regarding the sequencing of therapy for patients with BRAF wild-type advanced melanoma.
In conclusion, among treatment-naïve patients with BRAF wild-type advanced melanoma, a single-agent first-line PD-1 inhibitor followed by second-line IPI was the most costeffective strategy. The first-line treatment approach of NIVO + IPI, followed by second-line chemotherapy, was not found to be cost-effective on the basis of currently accepted WTP thresholds. In these patients, treatment strategy with sequential, single-agent immune checkpoint inhibition, compared with concurrent therapy, seems to be significantly more cost-effective, while also producing a comparable degree of tumor reduction and improved patient survival.
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